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and clinical factors associated with gout flares during the 
12-month follow-up period. There were 8905 patients iden-
tified as the final cohort and 68 % of these patients had one 
or more gout flares during the 12-month follow-up: 2797 
patients (31 %) had 0 gout flares, 4836 (54 %) had 1–2 
gout flares, and 1272 patients (14 %) had ≥3 gout flares. 
Using a multivariate regression analyses, factors indepen-
dently associated with 1–2 gout flares and ≥3 gout flares 
versus no gout flares were similar, however, with slight 
differences, such as younger patients were more likely to 
have 1–2 gout flares and patients ≥65 years of age had ≥3 
gout flares. Factors such as male gender, not attaining sUA 
goal, having ≥3 comorbidities, diuretics use, no changes in 
initial ULT dose, and not adhering to ULT all were asso-
ciated with gout flares versus no gout flares. Using a new 
method to identify gout flares, we had the opportunity to 
compare our findings with the previous studies. Our study 
findings echo other previous studies where older patients, 
male, diuretics, having a greater number of comorbidities, 
and non-adherence are more likely to have more gout flares 
during the first year of newly initiating ULT. There is an 
unmet need for patients with gout to be educated and man-
aged more closely, especially during the first year.
Keywords Gout · Gout flares · Urate-lowering therapy · 
Adherence · Serum uric acid goal
Introduction
Acute gout flare is the most common manifestation of gout 
and has been described as an acute inflammatory reaction 
with red, swollen, and painful joints [1, 2]. Gout and any of 
its clinical presentation, such as flares, tophi, and joint dam-
age, are due to urate crystal deposits in joints and tissues. 
Abstract Gout flares have been challenging to identify 
in retrospective databases due to gout flares not being well 
documented by diagnosis codes, making it difficult to con-
duct accurate database studies. Previous studies have used 
different algorithms, and in this study, we used a computer-
based method to identify gout flares. The objectives of this 
study were to identify gout flares in gout patients newly ini-
tiated on urate-lowering therapy and evaluate factors asso-
ciated with a patient experiencing gout flares after starting 
drug treatment. This was a retrospective cohort study iden-
tifying gout patients newly initiated on a urate-lowering 
therapy (ULT) during the study time period of January 1, 
2007–December 31, 2010. The index date was the first 
dispensed ULT prescription during the study time period. 
Patients had to be ≥18 years of age on index date, have no 
history of prior ULT prescription during 12 months before 
index date, and were required to have 12 months of contin-
uous membership with drug benefit during pre-/post-index. 
Electronic chart notes were reviewed to identify gout flares; 
these reviews helped create a validated computer-based 
method to further identify patients with gout flares and 
were categorized into 0 gout flares, 1–2 gout flares, and ≥3 
gout flares during the 12 months post-index period. Mul-
tivariable logistic regression was used to examine patient 
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Previous studies have shown that maintaining serum uric 
acid (sUA) at target levels of <6 mg/dl and adhering to a 
urate-lowering therapy (ULT) helps to reduce the frequency 
of gout flares [3–8]. The goal of gout flare treatment is pain 
relief through the reduction in inflammation and reduc-
tion in crystal dissolution [9]. Current treatments for gout 
flares include the use of nonsteroidal anti-inflammatory 
medications (NSAIDs), colchicine, and corticosteroids [9]. 
Gout flares are a common finding in gout patients, and it 
is important to identify them in clinical trials and obser-
vational studies so there is a better understanding on how 
to manage these patients appropriately [10]. Patients with 
gout flares have greater healthcare resource utilization, 
decreased quality of life, and loss of work productivity, 
leading to an increased economic burden for the patient 
as well as the healthcare system [6, 11–16]. Thus, it is 
important to learn how to better manage these patients, to 
decrease the economic burden, and to help reduce the fre-
quency of gout flares to improve their quality of life.
Gout flares can be challenging to identify in clinical 
databases due to gout flares not being well documented by 
diagnosis codes, thus making it difficult to conduct accu-
rate retrospective studies. Previous studies have used dif-
ferent algorithms consisting of diagnosis codes, radiology 
reports, pharmacy, and medical claims to identify gout 
flares [4, 5, 13–15, 17, 18]. However, these clinical surro-
gates have not been validated, which may have underesti-
mated or overestimated the rates of gout flares, have errors 
of sensitivity such as failure to identify true gout flares, or 
have errors in specificity such as identification of subjects 
who did not experience gout flares [4, 5, 13–15, 17–20]. 
The lack of standardized gout flare definition for observa-
tional studies demonstrates the intrinsic difficulty of flare 
identification [19]. Therefore, we created a computer-based 
method to automatically identify gout flares using natural 
language processing (NLP) and machine learning (ML) 
from electronic clinical notes [20]. Using this method, 
we had the opportunity to compare our findings with the 
algorithms used by previous studies. The objectives of this 
study were to (1) identify the number of gout flares in gout 
patients who were newly initiated on a ULT using a vali-
dated computer-based method and (2) identify patient and 
clinical factors associated with patients having gout flares 
compared with those who did not have gout flares during 
their first year on ULT.
Materials and methods
Study setting and dataset
Kaiser Permanente Southern California (KPSC) provides 
integrated, comprehensive medical services to 3.6 million 
members through its own facilities, which includes 14 hos-
pitals, 202 outpatient facilities, and a centralized laboratory. 
Every member receives a unique medical record number 
that they keep for life. This allows the member to be linked 
to various clinical and administrative databases includ-
ing member enrollment and benefits, inpatient and outpa-
tient visits, laboratory test results, and drug dispensing. All 
aspects of care and interactions with the healthcare delivery 
system are identified in a comprehensive electronic medical 
record (EMR) system. In addition, care delivered outside 
KPSC is identified by a claims system. The KPSC mem-
bership represents 15 % of the population in the Southern 
California region and closely mirrors the Southern Califor-
nia population; it is racially diverse and includes the entire 
socioeconomic spectrum [21, 22]. The institutional review 
board for KPSC approved this study.
Design and study population
A retrospective cohort database analysis was conducted 
during the study time period of January 1, 2007–Decem-
ber 31, 2010. Patients were included if they received a pre-
scription for a ULT (allopurinol, febuxostat, or probenecid) 
during the study time period; the index date was defined 
as the patient’s first ULT prescription identified during 
the study time period. Patients had to be ≥18 years of age 
at time of index date and were required to have at least 
12 months of KPSC membership eligibility including drug 
benefits prior to their index date, index date, and 12 months 
post-index. Enrollment gaps of ≤30 days were considered 
continuous enrollment. Eligible patients were required to 
have two outpatient gout diagnoses [International Classifi-
cation of Diseases, Ninth Revision, Clinical Modification 
(ICD-9-CM) code 274.xx] ≥30 days apart or one inpatient 
gout diagnosis code in any position anytime during the 
study time period. We identified patients newly initiating 
an ULT prescription if they had no ULT prescription dur-
ing the 12 months prior to their index date. Patients were 
excluded if they had history of human immunodeficiency 
virus (HIV), a diagnosis code for chronic kidney disease 
(CKD) stage 5 or an estimated glomerular filtration rate 
(GFR) <15 ml/min/1.73 m2, history of dialysis, active can-
cer, current chemotherapy, or kidney stones/nephrolithiasis 
(Fig. 1). Each exclusion criteria was applied to limit the 
patient population to those whose primary indication for 
ULT was gout. All patients had to have chart notes availa-
ble electronically; patients with only telephone notes, nurs-
ing notes, or no chart notes were excluded (Fig. 1).
Identifying gout flares
In previous studies [4, 5, 13–15, 17, 18], gout flares were 
identified using ICD-9-CM codes, the use of ULT, the use of 
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symptomatic gout flare medications, and healthcare resource 
utilization. In this study, we used a validated computer-
based method to identify gout flares from free-text clini-
cal notes; the published data and study findings are avail-
able elsewhere [20]. As an overview, a search system (beta 
version) was first created in which search keywords were 
applied to chart notes. All chart notes for 100 patients were 
reviewed, and learning from this beta review was imple-
mented to improve the algorithm for the second step, which 
was defined as the training dataset. The training dataset was 
created such that a different 100 patients were selected and 
chart notes were reviewed. Lastly, the refined computer 
methodology was applied to a final ‘gold standard’ set of 
progress notes. This method achieved a 82.1 % sensitivity, 
91.5 % specificity, 77.9 % positive predictive value (PPV), 
and 93.4 % negative predictive value (NPV) for identifying 
gout flares at the note level [20]. Consistent with prior stud-
ies [4, 5, 13–15, 17, 18], gout flares and their attendant care 
were assumed to last for a minimum of 30 days. Two flares 
within one 30-day period were counted as one flare. Once 
gout flares were identified, we categorized patients into the 
following groups during the 12 months of follow-up: 0 gout 
flares, 1–2 gout flares, and ≥3 gout flares.
Covariates and measures
Baseline characteristics (during the 12 months prior to 
the index date and index date) included age, sex, race, 
Fig. 1  Sample selection 
flowchart
Patients with a gout diagnosis anytime during 1/1/2007
to 12/31/2010
N=29,813
Continuous membership eligibility and drug benefit
during 12 months prior to index date
N= 26,121
No history of ULT prescription 12 months
prior index date N= 8, 863
Patients with active HIV*; CKD Stage 5; History of
dialysis; any active cancer; Current chemotherapy;
Lab eGFR <15 ml/min/1.73m2; Kidney stones/
nephrolithiasis; non-crystal arthropathies.
Total N=8,568
Without continuous membership eligibility and drug
benefit in health plan 12 months prior index date
N=3,611
History of ULT prescription 12 months prior index date
N= 7,708
Patients on an ULT during 1/1/2007 to 12/31/2010
N= 44,959 (index date)
Age <18 years of age
N=81
Age > 18 years of age on index date
N=29,732
Patients meet the inclusion criteria
N= 17,399
Patients with 12 months of follow-up
N= 16,571
Patients with less than 12 months of follow-up
N= 828
Patients have electronic chart notes during 12
months post index to identify gout flares using
NLP* N= 8,828 (Final Cohort)
Patients whom do not have any chart notes or only
telephone notes N= 35
*Human immunodeficiency virus (HIV); chronic kidney disease (CKD); estimated glomerular filtration rate (eGFR); natural
language processing (NLP).
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comorbid conditions, anti-inflammatory plus other con-
comitant medication use, initial dose of ULT, sUA levels, 
renal function, and prescriber specialty. Comorbid condi-
tions included alcohol use, cardiovascular disease, diabetes, 
hypertension, other arthritic conditions, and obesity. Base-
line GFR levels for renal function and baseline sUA lev-
els were measured up to 12 months prior to the index date, 
and if patients had multiple baseline sUA levels available, 
the measurement obtained most proximate to the index 
date was used. Prescription anti-inflammatory medications 
[nonsteroidals (NSAIDS), colchicine, or corticosteroids] 
and concomitant medications (antihypertensives, diuret-
ics, anti-hyperlipidemics, anti-diabetics) were all identified 
from electronic dispensing records. The initial dose of ULT 
was calculated using pharmacy data which included quan-
tity number, strength, day’s supply, and directions from the 
dispensed prescription. Prescriber specialty was determined 
at the time of the index dispensed ULT prescription and 
was categorized as primary care, rheumatologist, or other.
Outcomes
Outcomes of interest were identified during post-index for 
each of the gout flare groups. Outcomes included changes 
in ULT therapy from baseline such as dose escalation, dose 
equal, and dose decrease; adherence to ULT being meas-
ured using proportion of days covered (PDC) method; uti-
lization of anti-inflammatory therapies during post-index; 
and sUA goal attainment were identified during post-index. 
The sUA levels were evaluated for patients that had a base-
line and follow-up level. Patients were considered to have 
had ULT dose escalation if the final observed daily dose 
was greater than the index dose. Conversely, patients were 
considered to have had a dose decrease if the final daily 
ULT dose was less than the initial dose. If there was no 
change in the ULT dose, then it remained dose equal. PDC 
was calculated as the number of days with ULT drug dis-
pensed divided by the number of days in the specified time 
interval (365 days). We evaluated the PDC within the first 
12 months of initiating ULT. The PDC was dichotomized 
<80 % considered as non-adherent and ≥80 % considered 
adherent. Attainment of sUA goal was defined as the last 
follow-up sUA obtained after the index date with a value 
<6.0 mg/dl.
Statistical analyses
Unadjusted descriptive statistics summarized patient char-
acteristics of the study population where patients with 0 
gout flares were compared to patients with 1–2 gout flares 
and patients with 0 gout flares were compared to patients 
with ≥3 gout flares. Differences between these patients 
groups were tested using two-sided t test for continuous 
variables and the Chi-squared statistic for categorical vari-
ables. Multivariable logistic regression models were used 
to evaluate factors associated with patients having 1–2 gout 
flares versus patients with 0 gout flares and patients with 
≥3 gout flares versus patients with 0 gout flares. Factors 
including age, sex, race, severity of comorbid conditions, 
diuretic use, prescriber specialty, and anti-inflammatory 
medications were controlled for in the models. All data 
were analyzed using SAS version 9.2 (SAS Institute, Cary, 
NC, USA). p values <0.05 were considered to be statisti-
cally significant.
Results
There were 8828 gout patients identified as newly initiated 
on a ULT, using our selection criteria (Fig. 1); 68 % of these 
patients had one or more gout flares during the 12-month 
follow-up. With the application of our gout flare identifica-
tion method, 2780 patients (32 %) had 0 gout flares, 4798 
(54 %) had 1–2 gout flares, and 1250 patients (14 %) had 
≥3 gout flares during their 12 months post-index. Table 1 
summarizes baseline characteristics for these patients. 
Patients were predominantly male and Caucasian, and the 
most common comorbidities among the three groups were 
hypertension, dyslipidemia, and diabetes. Patients with ≥3 
gout flares had a higher percentage of comorbidities ver-
sus the other groups, and 47.3 % of them were ≥65 years 
of age. There were 5826 patients (65 %) with both a base-
line and follow-up sUA level. The mean baseline sUA level 
was lowest in the 0 gout flare group (8.73 ± 1.5 mg/dl) and 
highest in the ≥3 gout flare group (9.26 ± 1.8 mg/dl). The 
mean baseline eGFR was lowest in patients ≥3 gout flares 
(65.01 ± 18.09 ml/min). Patients with ≥3 gout flares had 
more use of antihypertensives and diuretics versus patients 
with gout flares. The initial ULT was most commonly pre-
scribed by primary care physicians; however, patients with 
0 gout flares had higher percentage of rheumatologists pre-
scribing their initial ULT. The mean initial baseline dose of 
ULT was higher in the patients with 0 gout flares versus 
those with 1–2 or ≥3 gout flares at baseline (Table 2).
Table 2 summarizes treatment adherence, ULT dose 
changes from baseline, sUA goal attainment, and the use of 
anti-inflammatory medications during follow-up. Patients 
with 0 gout flares were 74 % adherent to their ULT, while 
patients with 1–2 or ≥ 3 gout flares were 39 and 28 % 
adherent, respectively. Majority (95 %) had a ULT increase 
in dose during follow-up for the 0 gout flares; only 18 and 
8 % of patients with 1–2 and ≥3 gout flares had changes 
in their initial ULT doses during follow-up. The mean sUA 
level was (5.82 ± 0.7 mg/dl) for patients with 0 gout flares 
versus (8.64 ± 1.5 mg/dl) for patients with ≥3 gout flares 
(Table 2). In the 0 gout flares group, 91 % achieved sUA 
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Table 1  Baseline 
characteristics of study 
population categorized by gout 
flares
Patients with 1–2 gout flares were compared to no gout flares group, and patients with ≥3 gout flares were 
compared to no gout flares group
* p value of <0.05 was statistically significant
β Diseases of the cardiovascular or blood vessels: heart failure, ischemic heart disease, deep vein thrombo-
sis, cerebrovascular disease, peripheral vascular disease
+ Primary care prescriber consisted of family medicine and internal medicine
a NSAIDS nonsteroidal anti-inflammatory drugs
Patient and clinical characteristics Total patients N = 8828
No gout flares 1–2 gout flares ≥3 gout flares
N = 2780 (32 %) N = 4798 (54 %) N = 1250 (14 %)
Male n, (%) 2253 (81.0 %) 3801 (79.2 %) 991 (79.2 %)
Age (years) categories, n (%)
 <55 953 (34.2 %) 1970 (41.0 %)* 381 (30.5 %)*
 55–64 792 (28.4 %) 1123 (28.5 %)* 277 (22.2 %)*
 ≥65 1035 (37.2 %) 1705 (35.5 %) 592 (47.3 %)*
Race n, (%)*
 Caucasian 1187 (42.7 %) 1972 (41.1 %) 501 (40.1 %)
 African-American 392 (14.1 %) 747 (15.6 %) 229 (18.3 %)*
 Hispanic 536 (19.3 %) 970 (20.2 %) 268 (21.4 %)
 Asian/Pacific Islander 651 (23.4 %) 1076 (22.4 %) 240 (19.2 %)
 Other 14 (0.5 %) 33 (0.7 %) 12 (0.9 %)
Laboratory data
 sUA n, (%) 2032 (72.6 %) 3886 (80.4 %)* 1175 (92.4 %)*
 sUA (mg/dl) mean, SD 8.73 ± 1.55 8.93 ± 1.68 9.26 ± 1.81*
 eGFR n, (%) 2280 (81.5 %) 3905 (80.7 %) 1088 (85.5 %)
 eGFR (ml/min/1.72 m2), mean, SD 65.01 ± 18.09 64.79 ± 18.28* 60.99 ± 18.96*
Comorbidities n, (%)
 Alcohol use 87 (3.1 %) 181 (3.7 %) 64 (5.0 %)*
 Diseases of the heartβ 460 (16.4 %) 835 (17.3 %) 308 (24.2 %)*
 Diabetes mellitus 676 (24.2 %) 1016 (21.0 %) 313 (24.6 %)
 Dyslipidemia 1641 (58.7 %) 2679 (55.4 %) 716 (56.3 %)
 Hypertension 2001 (71.9 %) 3367 (69.6 %) 949 (74.6 %)
 Obesity 641 (22.9 %) 1168 (24.2 %) 302 (23.7 %)
 Osteoarthritis 469 (16.9 %) 902 (18.8 %) 310 (24.8 %)*
 Rheumatoid arthritis 17 (0.6 %) 32 (0.7 %) 16 (1.3 %)*
Anti-inflammatory medication, n, (%)
 NSAIDSa 1510 (54.3 %) 3199 (66.7 %)* 839 (67.1 %)*
 Corticosteroids 454 (16.2 %) 1456 (30.1 %)* 607 (47.7 %)*
 Colchicine 924 (33.0 %) 2515 (52.0 %)* 816 (64.2 %)*
 Any of the above 2069 (74.4 %) 4377 (91.2 %)* 1192 (95.4 %)*
Concomitant medications n, (%)
 Antihypertensives 2091 (74.8 %) 3469 (71.8 %) 970 (76.3 %)
 Diuretics 1331 (47.6 %) 2345 (48.5 %) 701 (55.1 %)*
 Anti-hyperlipidemics 1391 (49.8 %) 2199 (45.5 %) 590 (46.5 %)
 Anti-diabetics 556 (19.9 %) 807 (16.7 %)* 245 (19.3 %)
Initial ULT prescriber specialty n, (%)*
 Primary care prescriber+ 2027 (72.9 %) 4078 (84.9 %)* 1086 (86.9 %)*
 Rheumatologist 509 (18.3 %) 241 (5.0 %)* 13 (1.0 %)*
 Other 244 (8.8 %) 524 (10.9 %) 151 (12.1 %)
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goal compared with 45.8 % in the 1–2 gout flare group 
and only 21.2 % in the ≥3 gout flares group. There was 
also higher utilization of any anti-inflammatory medica-
tion for patients with flares versus those with no gout flares 
(Table 2).
Using multivariate logistic regression analysis, we iden-
tified patient and clinical factors that were independently 
associated with patients who were having gout flares versus 
patients who were not having gout flares (Table 3). Factors 
associated with 1–2 gout flares and ≥3 gout flares versus 
no gout flares were similar but more pronounced in those 
with more flares (≥3 flares). Age ≥ 65, male gender, and 
having ≥3 comorbidities were associated with increased 
rate of flares. Patients on diuretics were 19 % more likely 
to have 1–2 gout flares and 23 % more likely to have ≥3 
more gout flares. Other factors such as having index ULT 
prescribed by primary care, and higher sUA levels were 
all associated with an increased likelihood of having gout 
flares.
Discussion
This is the first study to identify gout flares utilizing a novel 
validated NLP + ML computer-based algorithm using text 
searches of clinical notes in EMR. This method provided 
results with a much higher sensitivity and specificity, when 
compared to the other database algorithm methods: 82.1 % 
sensitivity, 91.5 % specificity, 77.9 % positive predictive 
value (PPV), and 93.4 % negative predictive value (NPV) 
for identifying gout flares at the note level [20]. Compared 
with other studies using code-based algorithms to identify 
flares, the percentage of patients with ≥1 flare is 68 % in 
our study, compared with 11 % found by Primatesta et al. 
[25], 35 % by Sarawate et al. [5], 40.9 % by Wu et al. [15], 
and 45.2 % by Saseen et al. [17]. These differences may 
be due to the fact that patients often manage their flares at 
home without entering the healthcare system and generat-
ing codes. Providers then document the flares in progress 
notes at the next scheduled visit; thus, causal references in 
Table 2  Patient outcomes 
during 12 months post-index
Patients with 1–2 gout flares were compared to no gout flares group, and patients with ≥gout flares were 
compared to no gout flares group
* p value of 0.05 was statistically significant
Outcomes Total patients: N = 8828
No gout flares 1–2 gout flares ≥3 gout flares
N = 2780 N = 4798 N = 1250
Adherence to ULT (PDC  %)
 Adherent (PDC ≥ 80 %) 2042 (73.5 %) 1861 (38.8 %)* 352 (28.2 %)*
 Non-adherent (PDC < 80 %) 738 (26.5 %) 2937 (61.2 %)* 897 (71.8 %)*
ULT treatment information, n (%)
 Dose increase 2610 (94.6 %) 791 (16.5 %)* 67 (5.3 %)*
 Dose equal 153 (5.5 %) 3927 (81.8 %)* 1146 (91.7 %)*
 Dose decrease 17 (0.6 %) 80 (1.7 %)* 37 (3.0 %)*
Laboratory data at end of follow-up
 sUA, n (%) 1559 (56.0 %) 3150 (65.1 %)* 1117 (88.0 %)*
 sUA levels, mean, SD 5.82 ± 0.73 7.57 ± 1.98* 8.64 ± 1.56*
 At goal <6.0 mg/dl) (%) 91.4 % 45.8 %* 21.2 %*
Anti-inflammatory medication during 12 months post-index, n (%)
 NSAIDS 1745 (62.8 %) 3611 (75.2 %)* 954 (76.3 %)*
 Corticosteroids 652 (23.38 %) 2006 (41.5 %)* 875 (68.9 %)*
 Colchicine 1065 (38.08 %) 2994 (61.9 %)* 1036 (81.4 %)*
 Any of the above 2288 (82.3) 4658 (97.0 %)* 1242 (99.4 %)*
ULT initial and last doses, mean, SD
 Initial allopurinol dose, mean, SD 202.94 ± 100.54 202.76 ± 120.50 194.18 ± 100.35
 Ending allopurinol dose, mean, SD 230.41 ± 109.16 218.80 ± 99.85* 206.53 ± 98.33*
 Initial Febuxostat dose, mean, SD 60.00 ± 28.28 50.00 ± 18.52* 35.79 ± 8.38*
 Ending Febuxostat dose, mean, SD 53.82 ± 22.73 52.00 ± 19.32 45.57 ± 21.33*
 Initial probenecid dose, mean, SD 690.00 ± 362.86 681.82 ± 429.18 590.52 ± 218.14*
 Ending probenecid dose, mean, SD 926.88 ± 403.80 789.72 ± 364.12* 752.00 ± 268.74*
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the notes may not be coded, and within a traditional sys-
tem, the true incidence of gout flares maybe underreported. 
The study population along with the definition of gout flare 
may also be different in our study [4, 5, 13–15, 17, 18, 20].
Gout is associated with many comorbidities, such as obe-
sity, diabetes, renal insufficiency [11, 14, 23–28], and life-
style-related behaviors such as increase in alcohol intake, 
consumption of purine rich foods, in particular meats and 
oily fishes, which may complicate the adequate control of 
gout. Utilization of diuretics and chemotherapeutic agents 
is risk factor as well [26–28]. Comorbidities, being of male 
gender, age, and lifestyle-related behaviors complicate the 
adequate control of gout [26–28]. Some of these are modifi-
able, and others are not modifiable [26, 29]. In this study, 
we found that patients with multiple comorbidities or ≥3 
comorbidities had an increase rate in flares [30]. These 
comorbidities included hypertension, dyslipidemia, car-
diovascular disease, and diabetes. The mean baseline eGFR 
was lowest in patients ≥3 gout flares, showing that renal 
function was more decreased in this group versus other 
groups. Patients ≥65 years had a higher incidence of ≥3 
gout flares versus in the other groups. This could be contrib-
uted to having more comorbidities, being older, and multiple 
concomitant therapies which may lead to inadequate control 
of gout; however, there are other studies discussing how age 
is not a risk factor for gout flares. These maybe contributed 
to different population, different definition of gout flares, 
and how a dataset may have been created [26–28, 31, 32].
The relationship between high sUA levels and the recur-
rent gout flares has been shown in previous studies [3–5]. 
Consistent with Halpern et al. and Sarawate et al., we 
found a positive relationship between sUA levels and gout 
flares. We also found that patients with no gout flares ini-
tially had lower sUA levels at baseline versus patients with 
gout flares [3]. The sUA levels during follow-up showed 
that patients at goal or having a sUA < 6 mg/dl had no gout 
flares or less frequent flares versus patients with frequent 
flares of ≥3 flares. In patients newly initiated on ULT, there 
have been temporal patterns of gout flares in which we see 
greater occurrence of gout flares during the first year with 
ULT use which decrease over time [3–5]. Patients at goal 
have less likelihood of gout flares, and those with a reduc-
tion in sUA levels with continuous ULT are associated with 
long-term periods of patients being free from gout flares 
[3, 7, 23, 24]. Poor adherence to ULTs is not successful in 
keeping sUA levels below goal and increases the incidence 
Table 3  Multivariate logistic 
regression of factors associated 
with patients with gout flares 
versus no gout flares during 
12-month follow-up in gout 
patients
OR odds ratio, CI Confidence interval
* Highlighted in bold means they are statistically significant
α Adjusted for sex, age, race, sUA levels, comorbidities, anti-inflammatory medications, diuretic use, and 
rheumatologist as a prescriber
Study covariates Patients with 1–2 flares versus  
patients with no gout flaresα
Patients with ≥3 flares versus 
patients with no gout flaresα
OR (95 % CI) OR (95 % CI)
Male patient (vs. female) 1.53 (1.22, 1.66) 1.95 (1.88, 2.12)*
Patient age categories
 <65 years (reference group) 1.00 1.00
 ≥65 years 0.94 (0.82, 1.16) 1.81 (1.16, 2.52)
Race
 Caucasian (reference group) 1.00 1.00
 African-American 1.02 (0.88, 1.18) 1.20 (0.98, 1.46)
 Hispanic 0.96 (0.84, 1.09) 1.06 (0.87, 1.29)
 Asian/Pacific Islander 1.03 (0.91, 1.17) 1.14 (0.95, 1.37)
sUA data
 sUA level above 6.0 mg/dl 1.64 (1.47, 1.88) 3.61 (3.37, 4.01)
Comorbidity
 1 comorbidity 0.68 (0.59, 0.91) 0.79 (0.69, 0.91)
 2 comorbidities 1.14 (0.96,1.24) 1.67 (1.31, 1.87)
 3 or more comorbidities 1.34 (1.13, 1.78) 1.93 (1.65, 2.27)
Other covariates
 Anti-inflammatory 2.65 (2.21, 3.19) 3.10 (2.51, 4.02)
 Diuretics 1.19 (1.05, 1.34) 1.23 (1.01, 1.57)
 Rheumatologist as initial pre-
scriber
0.79 (0.69, 0.91) 0.77 (0.66, 0.89)
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of gout flares [3–5, 23, 24]. There could be other factors 
associated with adherence which could not have been iden-
tified, but being non-adherent to ULT medication leads to 
gout flares and failure to adjust ULT therapy are modifiable 
causes of gout flare. Patients who had their ULT prescriber 
by Rheumatologists had less gout flares versus those where 
the index ULT prescribed by a non-Rheumatologist. Uti-
lization of anti-inflammatory medication during baseline 
period is positively related to the gout flares in this study; 
however, we do not know if these specific medications 
were used for gout flares, prophylaxis, or other reasons. We 
could not identify if patients took these medications prior 
to a gout flare since majority of patients may have self-
treated their attacks and thus could not calculate a rate. The 
NLP process identified colchicine use but generally could 
not distinguish when it was used for prophylaxis versus the 
use for gout flares. It was difficult to know whether patients 
were taking this medication as prescribed or consistently 
versus inconsistently; thus, we could evaluate the dura-
tion of use. Our study is consistent with gout management 
guidelines [9] and other studies that the use of prophylaxis 
therapy [30] is needed to help control gout flares, and this 
could also be the possible reason for the increase use of 
anti-inflammatory medications.
As with any retrospective study, there are some limitations 
that need to be addressed. One is investigator dependence 
on the availability and accuracy of the pharmacy and medi-
cal records to identify the study population. To help alleviate 
this concern, we identified patients with gout using two gout 
diagnoses ≥30 days apart or one inpatient gout diagnosis 
code, in addition to a prescription for urate-lowering therapy. 
Another limitation is that the NLP may not be able to identify 
all patients with acute gouty flares even with the search cri-
teria being established, since gout flares are sometimes self-
managed at home or that gout flares are scantly documented. 
Our validated algorithm with 82.1 % sensitivity and 91.5 % 
specificity was shown to be superior to traditional meth-
ods of identifying gout [20]. Another limitation is that the 
NLP + ML computer-based method is currently not available 
in other health plans. However, discussions with other EMR 
data health plans are in process. Some patients may have 
filled their medication prescriptions at other non-KPSC phar-
macies, and this cannot be identified or patients purchasing 
their NSAIDs from over the counter for possible gout flares. 
Also, utilization of NSAIDs could also be used for other 
conditions, and not just prophylactic use for gout flares. We 
added the criteria to the selection of the study sample to only 
include patients who have continuous membership eligibil-
ity and drug benefit 12 months pre-index and 12 month post-
index. When measuring adherence, we do not know whether 
the medication was really taken even though it was picked up 
and recorded in our system. In our health system, we did not 
identify any patients treated with ACTH for gout flares, and 
thus, this therapy was not included in the treatment of gout 
flares. Lastly, patients with CKD stage 5 were excluded, and 
these risk factors are not applied to this population.
In this study, we used a new and different method to 
identify gout flares. The validated computer-based method 
produced findings consistent with other studies, where 
patients older in age, male, not attaining sUA goal of 
<6 mg/dl, non-adherence to ULT, diuretic use, and more 
comorbidities are associated with more gout flares during 
the first year of newly initiating ULT. Patient education and 
physician involvement are two keys to reduction in gout 
flares, especially during the first year where most gout flares 
occur from initiation of ULT. Patients who follow the rec-
ommendations to initiate ULT with a low starting dose or 
increase the ULT slowly tend to have fewer adverse events 
[32, 33]. Currently, most of the management of gout occurs 
in primary care setting and acute gout management is con-
sidered suboptimal. In this study, we see that majority of 
the patients do not have follow-up sUA levels and there is 
lack of increase to the initial ULT prescription dose. Issues 
from lack of adherence to suggested treatment, relative con-
traindications such as hypertension, metabolic syndrome, or 
chronic kidney disease are among the reasons that gout care 
and treatment is difficult. These can all lead to continued 
gout flares. Computer-based methods such as NLP + ML 
can be used in many healthcare systems where EMR data 
are available to identify at risk patients, and programs 
designed to address the modifiable risks can be instituted. 
More studies related to computer-based methods, evaluating 
medical resource use, and economic impact of these patients 
in a managed care integrated system would add to the body 
of evidence leading to better care for these patients. This 
study confirms that using a novel computer-based method 
identifies the importance of modifiable risk factors in the 
prevention of acute gout flares. ULT dose adjustment and 
compliance are two factors which can be addressed to lower 
the frequency and severity of acute gout flares.
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